Understanding and treating necrotizing enterocolitis in premature infants
Molecular and metabolic signaling in necrotizing enterocolitis
This study is looking into necrotizing enterocolitis (NEC), a serious gut problem that mainly affects premature babies, to find out how it happens and to create better treatments to help these little ones.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-11047553 on NIH RePORTER |
What this research studies
This research focuses on necrotizing enterocolitis (NEC), a severe gastrointestinal disease that primarily affects premature infants. The study aims to uncover the biological mechanisms behind NEC and develop new treatment options to combat this life-threatening condition. By investigating the inflammatory responses and bacterial interactions in the intestines of affected infants, the research seeks to provide insights that could lead to effective therapies. The principal investigator has extensive experience in this field, having contributed significantly to the understanding of NEC over the past two decades.
Who could benefit from this research
Good fit: Ideal candidates for this research are premature infants who are at risk of developing necrotizing enterocolitis.
Not a fit: Patients who are not premature or do not have gastrointestinal diseases will likely not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to novel treatments that significantly reduce mortality and improve outcomes for premature infants suffering from NEC.
How similar studies have performed: Previous research has shown promise in understanding NEC and developing treatments, but this specific approach aims to address critical unanswered questions in the field.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Hackam, David J — Johns Hopkins University
- Study coordinator: Hackam, David J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.